Market Overview

JMP Feeling Mostly Good On 4 Drug, Healthcare Stocks


Four companies in the healthcare and pharmaceuticals sectors posted mixed results that left analysts at JMP Securities mostly feeling good.

Adeptus Health Inc's (NYSE: ADPT) closed Friday up nearly 2 percent on strong quarterly results.

JMP analyst Peter L. Martin expects Adeptus shares to soon fall back in the face of a potential offering of stock from its
largest shareholder and private equity sponsor Sterling Partners.

Martin, who maintained an Outperform rating on Adeptus and boosted his target to 10 percent to $44, said the potential offering could make "an ideal entry point" for investors.

Adeptus will likely exceed expectations given its pace for opening new hospitals and the opportunities for free-standing emergency departments, according to Martin.

Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) closed Friday up 1 percent at $11.43 after posting results that missed expectations along with an upbeat outlook.

JMP's Jason N. Butler maintained an Outperform rating and $30 target.

Butler cited potential for the company's recently launched Hetlioz sleep disorder drug as well as the pending rollout of its Fanapt anti-psychotic treatment.

Select Medical Holdings Corporation (NYSE: SEM) missed quarterly expectations and closed down Friday at $13.47, off nearly 4 percent.

Martin maintained an Underperform rating on Select along with an $11 target. Select's recent changes in its long-term care hospitals' policy will produce "a significant headwind to profitability," Martin said.

Ariad Pharmaceuticals, Inc. (NASDAQ: ARIA) closed Friday at $8.06, up nearly 11 percent after posting better-than-expected fourth-quarter results.

JMP's Michael G. King maintained an Outperform rating and $8 target on Ariad, citing recent performance and noting the development-stage drug company, has sufficient cash to carry it through 2016.

Latest Ratings for ADPT

Nov 2016Goldman SachsDowngradesBuyNeutral
Nov 2016Stephens & Co.DowngradesOverweightEqual-Weight
Nov 2016JefferiesDowngradesBuyHold

View More Analyst Ratings for ADPT
View the Latest Analyst Ratings

Posted-In: Jason N. Butler JMP Securities Michael G. King Peter L. MartinPrice Target Reiteration Analyst Ratings


Related Articles (ARIA + ADPT)

View Comments and Join the Discussion!

Are These 3 Community Banks Investment Opportunities? Analysts Discuss

Best And Worst ETFs Of The Week Amid Greek Relief Deal